Requip and Malabsorption - a phase IV clinical study of FDA data

Summary:

Malabsorption is reported as a side effect among people who take Requip (ropinirole hydrochloride), especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months also take Cymbalta, and have Pain.

The phase IV clinical study analyzes which people have Malabsorption when taking Requip. It is created by eHealthMe based on reports of 21,866 people who have side effects when taking Requip from the FDA, and is updated regularly.

What is Requip?

Requip has active ingredients of ropinirole hydrochloride. It is often used in restless leg syndrome. eHealthMe is studying from 22,949 Requip users. Check the latest studies of Requip.

What is Malabsorption?

Malabsorption (a state arising from abnormality in absorption of food nutrients across the gastrointestinal (gi) tract) is found to be associated with 710 drugs and 1,085 conditions by eHealthMe. Check the latest studies of Malabsorption.

On Dec, 01, 2025

21,866 people reported to have side effects when taking Requip.
Among them, 20 people (0.09%) have Malabsorption.

Among these 20 people:

How long have people been on Requip when they have Malabsorption? *

What is the gender of people who have Malabsorption when taking Requip? *

female: 82.35 %
male: 17.65 %

What is the age of people who have Malabsorption when taking Requip? *

What are other drugs people take besides Requip? *

What are other side effects people have besides Malabsorption? *

Nausea (feeling of having an urge to vomit): 9 people, 45.00%
Pain: 8 people, 40.00%
Nausea And Vomiting: 8 people, 40.00%
Dizziness: 8 people, 40.00%
Dyspnea (difficult or laboured breathing): 8 people, 40.00%
Abdominal Pain: 7 people, 35.00%
Drug Ineffective: 7 people, 35.00%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 7 people, 35.00%
High Blood Pressure: 7 people, 35.00%
Internal Hernia (protrusion of an intraperitoneal viscous into a compartment or under a constricting band within the abdominal cavity): 6 people, 30.00%

What are the existing conditions these people have? *

Pain: 8 people, 40.00%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 7 people, 35.00%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 4 people, 20.00%
Stress And Anxiety: 3 people, 15.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 15.00%
High Blood Pressure: 3 people, 15.00%
Vitamin D Decreased: 2 people, 10.00%
Gastrointestinal Pain: 2 people, 10.00%
Back Pain: 2 people, 10.00%
Constipation: 2 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Requip and have Malabsorption?

- Check whether Malabsorption is associated with a drug or a condition (FREE)
- Predict drug outcomes for up to one year with AI (FREE)
- Get an AI agent to monitor your drugs continuously (FREE)

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Requip:

Requip (22,949 reports)

Malabsorption treatments and more:

Malabsorption (8,910 reports)

Browse all side effects of Requip:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Malabsorption:

Malabsorption (710 drugs)

Browse all the conditions that are associated with Malabsorption:

Malabsorption (1,085 conditions)

Drugs similar to Requip and Malabsorption :

How the study uses the data?

The study uses data from the FDA. It is based on ropinirole hydrochloride (the active ingredients of Requip) and Requip (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.